0001209191-21-064378.txt : 20211115 0001209191-21-064378.hdr.sgml : 20211115 20211115060516 ACCESSION NUMBER: 0001209191-21-064378 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211111 FILED AS OF DATE: 20211115 DATE AS OF CHANGE: 20211115 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Booth Andrew CENTRAL INDEX KEY: 0001834411 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39781 FILM NUMBER: 211406016 MAIL ADDRESS: STREET 1: C/O ABCELLERA BIOLOGICS INC. STREET 2: 2215 YUKON STREET CITY: VANCOUVER STATE: A1 ZIP: V5Y 0A1 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AbCellera Biologics Inc. CENTRAL INDEX KEY: 0001703057 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2215 YUKON STREET CITY: VANCOUVER STATE: A1 ZIP: V5Y 0A1 BUSINESS PHONE: (604) 559-9005 MAIL ADDRESS: STREET 1: 2215 YUKON STREET CITY: VANCOUVER STATE: A1 ZIP: V5Y 0A1 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-11-11 0 0001703057 AbCellera Biologics Inc. ABCL 0001834411 Booth Andrew C/O ABCELLERA BIOLOGICS INC. 2215 YUKON STREET VANCOUVER A1 BRITISH COLUMBIA, CANADA 0 1 0 0 Chief Financial Officer Common Shares 2021-11-11 4 P 0 53500 14.74 A 53500 D Common Shares 2021-11-11 4 P 0 14000 14.61 A 130959 I By spouse The price reported in Column 4 is a weighted-average price. These shares were sold in two transactions at prices $14.60 and $14.67. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted-average price. These shares were sold in two transactions at prices $14.67 and $14.75. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Tryn Stimart, attorney-in-fact 2021-11-15